Fig. 2

Analysis of therapeutic efficacy based on peripheral blood parameters. A-G Differences between DCB and NDB groups at baseline and post ICB treatment in the training, Nonparametric Mann-Whitney test was used for comparisons (using continuous variables). H Nomogram for predicting ICB treatment response of NSCLC patients. I Calibration curves of the nomogram. J ROC curves in the training set. K ROC curves in the validation set. DCB, Durable clinical benefit; NDB, None durable benefit; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; NSCLC, Non-small cell lung cancer; AUC, Area under the curve; ROC, receiver operating characteristic curve